These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39250644)

  • 21. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study.
    Patel NJ; Wang X; Fu X; Kawano Y; Cook C; Vanni KMM; Qian G; Banasiak E; Kowalski E; Zhang Y; Sparks JA; Wallace ZS
    Semin Arthritis Rheum; 2023 Feb; 58():152108. PubMed ID: 36347211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project.
    Spiteri G; D'Agostini M; Abedini M; Ditano G; Collatuzzo G; Boffetta P; Vimercati L; Sansone E; De Palma G; Modenese A; Gobba F; Liviero F; Moretto A; dell'Omo M; Fiordi T; Larese Filon F; Mauro M; Violán C; Mates D; Oravec Bérešová J; Monaco MGL; Carta A; Verlato G; Porru S
    Infection; 2024 Aug; 52(4):1347-1356. PubMed ID: 38326526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
    Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
    BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shift in SARS-CoV-2 variants of concern from Delta to Omicron was associated with reduced hospitalizations, increased risk of breakthrough infections but lesser disease severity.
    Mwendwa F; Kanji A; Bukhari AR; Khan U; Sadiqa A; Mushtaq Z; Nasir N; Mahmood SF; Aamir UB; Hasan Z
    J Infect Public Health; 2024 Jun; 17(6):1100-1107. PubMed ID: 38714122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breakthrough COVID-19 Infections after Booster SARS-CoV-2 Vaccination in a Greek Cohort of People Living with HIV during the Delta and Omicron Waves.
    Protopapas K; Thomas K; Moschopoulos CD; Oktapoda E; Marousi E; Marselou E; Stamoulis N; Filis C; Kazakou P; Oikonomopoulou C; Zampetas G; Efstratiadou O; Chavatza K; Kavatha D; Antoniadou A; Papadopoulos A
    Biomedicines; 2024 Jul; 12(7):. PubMed ID: 39062187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
    Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
    JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV.
    Casado JL; Vizcarra P; Martín-Colmenarejo S; Del Pino J; Gomez-Maldonado S; Martín-Hondarza A; Vallejo A
    AIDS; 2023 May; 37(6):877-882. PubMed ID: 36779501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.
    Stouten V; Hubin P; Haarhuis F; van Loenhout JAF; Billuart M; Brondeel R; Braeye T; Van Oyen H; Wyndham-Thomas C; Catteau L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.
    Gillot C; Tré-Hardy M; Cupaiolo R; Blairon L; Wilmet A; Beukinga I; Dogné JM; Douxfils J; Favresse J
    Virology; 2024 Jul; 595():110082. PubMed ID: 38636363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Hasan MR; Coyle P; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Butt AA; Al Romaihi HE; Al-Thani MH; Al Khal A; Bertollini R
    JAMA; 2021 Nov; 326(19):1930-1939. PubMed ID: 34724027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.
    Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC
    J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections.
    Sejdic A; Hartling HJ; Holler JG; Klingen Gjærde L; Lindegaard B; Dungu AM; Gnesin F; Møller MEE; Teglgaard RS; Niemann CU; Brooks PT; Jørgensen CS; Franck KT; Fischer TK; Marquart HV; Harboe ZB; Ostrowski SR
    Front Immunol; 2024; 15():1360843. PubMed ID: 38903511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus.
    Casado-Fernández G; Cantón J; Nasarre L; Ramos-Martín F; Manzanares M; Sánchez-Menéndez C; Fuertes D; Mateos E; Murciano-Antón MA; Pérez-Olmeda M; Cervero M; Torres M; Rodríguez-Rosado R; Coiras M
    Front Immunol; 2024; 15():1362621. PubMed ID: 38812512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination status and disease severity of COVID-19 in different phases of the pandemic.
    Yang X; Shi F; Zhang J; Gao H; Chen S; Olatosi B; Weissman S; Li X
    Hum Vaccin Immunother; 2024 Dec; 20(1):2353491. PubMed ID: 38832632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study.
    Xueying Y; Zhang J; Olatosi B; Weissman S; Li X
    BMJ Open; 2022 Aug; 12(8):e067095. PubMed ID: 35998950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV.
    Hechter RC; Qian L; Liu IA; Sy LS; Ryan DS; Xu S; Williams JTB; Klein NP; Kaiser RM; Liles EG; Glanz JM; Jackson LA; Sundaram ME; Weintraub ES; Tseng HF
    JAMA Netw Open; 2024 Jun; 7(6):e2415220. PubMed ID: 38842808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.
    Hönning A; Tomczyk S; Hermes J; Grossegesse M; Hofmann N; Michel J; Neumann M; Nitsche A; Hoppe B; Eckmanns T; Schmidt-Traub H; Zappel K
    BMC Infect Dis; 2024 Apr; 24(1):436. PubMed ID: 38658874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.